Michel-Ramírez JM, Lujano-Pedraza H, Gaona-Valle LS, Muñoz-Lumbreras EG, Valdéz-Colín JA, Gaytán-Murguía M, Manríquez-Buelna RE, Quezada-León CS, Arias-Patiño JJG

Language: English
References: 10
Page: 1-6
PDF size: 238.87 Kb.

ABSTRACT

Objective: To develop and validate a simple self-administered questionnaire to evaluate ureteral stent discomfort.
Materials & Methods: A pilot instrument based on the ussq was designed and structured, using the Delphi method. It was applied to 72 patients with an indwelling ureteral stent after semirigid ureteroscopy. The instrument was validated through the Cronbach’s alpha coefficient and Pearson’s correlation coefficient.
Results: The ureteral stent discomfort test (usdt) utilizes a Likert scale model, with 6 domains: 1-urinary symptoms, 2-pain, 3-daily life, 4-sexual life, 5-medical care/use of analgesics, and 6-quality of life, with 6, 2, 1, 1, 2, and 1 items, respectively. The more severe the symptoms, the higher the score, with a maximum score of 61 points. Validation studies made the questionnaire internally consistent (Cronbach 0.820) with good reliability (Pearson 0.850). The correlation of urinary symptoms (r = 0.929, p = 0.00), pain (r = 0.880, p = 0.00), daily life (r = 0.625, p = 0.00), and quality of life (r = 0.768, p = 0.00) of both questionnaires was statistically significant. Application time for the usdt (m = 1.8min sd = 0.76) was shorter than for the ussq (m = 8.3min sd = 0.76).
Limitations: The small sample size was a restriction. More patients are required to demonstrate the usdt’s effectiveness.
Value: The questionnaire is an easy-to-use tool for the simple evaluation of ureteral stent discomfort.
Conclusions: The usdt is a simple and rapid tool, comparable to the ussq, for evaluating ureteral stent-related symptoms.

REFERENCES

1. Regan SM, Sethi AS, Powelson JA, Goggins WC, Milgrom ML, Sundaram CP. Symptoms related to ureteral stents in renal transplants compared with stents placed for other indications. J Endourol. 2009;23(12):2047¨C50. doi: 10.1089/ end.2009.0112

2. Miyaoka R, Monga M. Ureteral stent discomfort: Etiology and management. Indian J Urol. 2009;25(4):455¨C60. doi: 10.4103/0970- 1591.57910

3. Chew BH, Knudsen BE, Nott L, Pautler SE, Razvi H, Amann J, et al. Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent comfort. J Endourol. 2007;21(9):1069¨C75. doi: 10.1089/ end.2006.0252

4. Al-Kandari AM, Al-Shaiji TF, Shaaban H, Ibrahim HM, Elshebiny YH, Shokeir AA. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol. 2007;21(7):698¨C702. doi: 10.1089/end.2007.9949

5. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060¨C4. doi: 10.1097/01.ju.0000049198.53424.1d

6. Leibovici D, Cooper A, Lindner A, Ostrowsky R, Kleinmann J, Velikanov S, et al. Ureteral stents: morbidity and impact on quality of life. Isr Med Assoc J. 2005;7(8):491¨C4.

7. Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for ¦Á-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011 Sep;186(3):928¨C 34. doi: 10.1016/j.juro.2011.04.061

8. T¨¹rk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Thomas K. EAU Guidelines of Urolithiasis. European Association of Urology; 2018.

9. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009;23(11):1913¨C7. doi: 10.1089/end.2009.0173

10. Stant LT, Aaen PH, Ridler NM. Comparing methods for evaluating measurement uncertainty given in the JCGM ¡®Evaluation of Measurement Data¡¯ documents. Measurement. 2016; 94:847¨C51. doi: 10.1016/j.measurement.2016.08.015